

Bacterial infection may trigger DRESS syndrome: an exceptional case of delayed hypersensitivity reaction occurring 22 months after allopurinol therapy

Ines Souilem¹, zgolli fatma¹, Ghozlane Lakhoul¹, Sarrah Kastalli¹, Riadh Daghfous¹, and Sihem El Aidli¹

¹Affiliation not available

March 17, 2023

Abstract

Drug-induced hypersensitivity syndrome also known as DRESS syndrome is considered as a severe and potentially life-threatening adverse drug reaction. The pathogenesis of DRESS syndrome is still partially understood. Prior research has implicated viral infection or reactivation, specifically, human herpes viruses 6 and 7, Epstein-Barr virus and cytomegalovirus.

We report a case of DRESS syndrome induced by allopurinol occurring 22 months after starting the treatment and which might have been triggered by concomitant infections.

A 72-year-old man was put on allopurinol in February 2021. Twenty months later, he was hospitalized for Klebsiella urinary tract infection associated with erysipelas that had evolved well after two weeks of antibiotherapy. On November 20, he presented a second episode of Enterococcus faecalis urinary tract infection. On December 5, he developed a pruritic maculopapular rash with fever (39.5°C). Skin examination showed a generalized infiltrated erythematous maculopapular eruption and facial edema. Complete blood counts showed total leucocyte count at $10.6 \times 10^3/\mu\text{l}$ with eosinophils at $1.58 \times 10^3/\mu\text{l}$ (14.9%). Histological findings were compatible with DRESS syndrome. Allopurinol was stopped. Skin condition improved within a month.

A prolonged delay between the start of treatment and the appearance of a febrile rash should never exclude the diagnosis of Dress syndrome or delay its management.

Keywords : DRESS syndrome, allopurinol, infection, pharmacovigilance

Introduction:

Drug-induced hypersensitivity syndrome also known as DRESS (drug reaction with eosinophilia and systemic symptoms)syndrome, is considered as a severe and potentially life-threatening adverse drug reaction. It is characterized by skin rash, fever, hematologic abnormalities (eosinophilia, atypical lymphocytes), lymphadenopathy and internal organ involvement [1]. Currently, the pathogenesis of DRESS syndrome is only partially understood. Prior research has implicated viral infection or reactivation. It is associated, specifically, with human herpes viruses 6 (HHV-6) and 7 (HHV-7), Epstein-Barr virus (EBV) and cytomegalovirus (CMV)[1,2].

We report a case of DRESS syndrome induced by allopurinol occurring 22 months after starting the treatment and which might have been triggered by concomitant infections.

This case was notified to the Tunisian Center of Pharmacovigilance on December 23th2022 under the registration number**3788/22** .

Case report: A 72-year-old diabetic man on insulin, with a history of coronary artery bypass surgery, was put on allopurinol in February 2021 for gout. Twenty months later, (October 22, 2022), he was hospitalized for Klebsiella urinary tract infection associated with erysipelas that had evolved well after two weeks of

antibiotherapy (ciprofloxacin and piperacillin-tazobactam). On November 20, he presented a second episode of *Enterococcus faecalis* urinary tract infection and received teicoplanin for a week. On December 5, he developed a pruritic maculopapular rash with fever estimated at 39.5°C. The eruption first appeared on his legs and quickly proceeded to involve the majority of his body including palms and soles. Skin examination showed a generalized infiltrated erythematous maculopapular eruption (figure 1) and facial edema without polyadenopathy. Labial mucosa and conjunctivae were not affected. The rest of the physical examination was normal. Complete blood counts showed total leucocyte count at $10.6 \times 10^3/\mu\text{l}$ with eosinophils at $1.58 \times 10^3/\mu\text{l}$ (14.9%). Renal and hepatic functions were normal. Histological findings showed vacuolisation of the epidermal basal cell layer and perivascular lymphocytic infiltrate in the dermis, compatible with DRESS syndrome. Allopurinol was stopped. Skin condition improved and laboratory parameters returned to normal rates within a month after the drug withdrawal and using oral corticosteroids (prednisolone).

Discussion:

The diagnosis of DRESS syndrome was made in this patient based on the criteria adopted by the European group RegiSCAR [3]. In our case, the score was four (probable case) because of: skin rash over 50% of body surface area (1 point), facial edema and infiltrated skin lesions (1 point), generalized lymphadenopathy (1 point) and eosinophilia at 14.9% (1 points). The responsibility of allopurinol in inducing DRESS syndrome was evaluated as I3 (C2S2) according to the updated French method of imputability because of the compatible delay (22 months after drug intake) and the favorable outcome after the medication withdrawal [4,5].

Despite that currently the pathogenesis of allopurinol-induced DRESS syndrome is only partially understood, it is thought to be multi-factorial and implicate at least three components[6]: first, the accumulation of allopurinol's metabolite which may directly cause cell damage. Second, genetic predisposition through specific human leukocyte antigen (HLA) allele's subtype. The third possible component is that DRESS syndrome, as a delayed hypersensitivity reaction, may induce the reactivation of viruses of the Herpes group by the activation of T lymphocytes. In fact, it has demonstrated that the TH1-type cytotoxic T cell response was directed against viral antigens and not against drugs. In this situation the drug promote the passage from a latent stage of infection to a viral reactivation, by increasing the viral replication either by a direct action on the virus itself, or by creating a state of immunosuppression[7]. This cascade reaction is thought to be accelerated by community-acquired bacterial and viral infections and can be observed in other stressful situations of immunosuppression such as hospitalizations in intensive care units [8].

The clinical presentation of DRESS syndrome is variable and occurs in response to a range of drugs, usually 3 weeks to 3 months after initiation. In the present case, allopurinol was being used over 22 months, but the clinical manifestations appeared, six weeks after the first urinary tract infection and 15 days after the second one, which is a suggestive delay.

Hence, we believe that these two infectious episodes, with the hospital stay, might have contributed to accelerate the cascade reaction by creating a state of immunosuppression and inducing a viral reactivation. This hypothesis might explain the longer delay, than generally accepted, between initiating allopurinol and the occurrence of DRESS syndrome. However, we could not determine the HHV-6, HHV-7, CMV and EBV reactivation, due to lack of the measurement kits at our laboratory. To the best of our knowledge, there has only been one patient diagnosed with DRESS syndrome after a long drug exposure. In that case, the patient had been treated for 12 months with sulphasalazine, and had undergone H1N1 vaccination 4 days prior to the symptoms. HHV 6 reactivation had been confirmed with a serological test [9].

Conclusion:

This case fits the clinical presentation of DRESS syndrome and occurred during drug therapy with allopurinol, a known causative agent. The onset of symptoms occurring 22 months after drug initiation has not previously been reported in the literature. Thus, a prolonged delay between the start of treatment and the appearance of a febrile rash should never exclude the diagnosis of Dress syndrome or delay its management.

References:

1. Choudhary S, McLEOD M, Torchia D, Romanelli P. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome. 2013;6.
2. Tohyama M, Hashimoto K, Yasukawa M, Kimura H, Horikawa T, Nakajima K, et al. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. *Br J Dermatol*. 2007;157:934-40.
3. Sasidharanpillai S, Ajithkumar K, Jishna P, Khader A, Anagha K, Binitha M, et al. RegiSCAR DRESS (drug reaction with eosinophilia and systemic symptoms) validation scoring system and Japanese consensus group criteria for atypical drug-induced hypersensitivity syndrome (DiHS): A comparative analysis. *Indian Dermatol Online J*. 2022;13:40.
4. Miremont-Salamé G, Théophile H, Haramburu F, Bégaud B. Causality assessment in pharmacovigilance: The French method and its successive updates. *Therapies*. 2016;71:179-86.
5. Montastruc JL. Pharmacovigilance and drug safety: Fair prescribing and clinical research. *Therapies*. 2022;77:261-3.
6. Myers CM, Miller JJ, Davis WD. Allopurinol-Induced Drug Reaction With Eosinophilia and Systemic Symptoms: A Case Report. *Adv Emerg Nurs J*. 2020;42:108-18.
7. Koike M, Kanno Y, Tomori K, Okada H, Suzuki H. Viruses may trigger allopurinol hypersensitivity syndrome. *Clin Kidney J*. 2008;1:273-4.
8. Descamps V, Ranger-Rogez S, Musette P, Barbaud A. Le DRESS (drug reaction with eosinophilia and systemic symptoms): une synergie médicaments-virus qui peut conduire en réanimation. *Reanimation*. 2011;20:223-7.
9. Hewitt N, Levinson M, Stephenson G. Drug reaction with eosinophilia and systemic symptoms associated with H1N1 vaccination. *Intern Med J*. 2012;42:1365-6.